|
KarXT Clinical Trials
6 actively recruiting trials across 4 locations
Also known as: BMS-986510, Xanomeline and Trospium Chloride capsule, BMS-986510
Pipeline
Phase 3: 6
Top Sponsors
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company3
- Bristol-Myers Squibb3
Indications
- Alzheimer's Disease6
- Psychosis Associated With Alzheimer's Disease2
- Alzheimer Disease2
- Agitation1
Homewood, Alabama2 trials
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Local Institution - 1029
Phase 3
Chandler, Arizona2 trials
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Chandler Clinical Trials, LLC
Phase 3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Local Institution - 2609
Phase 3
Fullerton, California1 trial
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Fullerton Neurology and Headache Center
Phase 3
Long Beach, California1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.